CompletedNot Applicable

Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo

China100 participantsStarted 2023-01-01

Plain-language summary

Sensorineural hearing loss (SNHL) accompanied by vertigo is a significant clinical challenge. Current conventional treatments often offer limited efficacy. This study evaluates the efficacy and safety of Gastrodin Acupoint Injection (GAI) as an adjunctive therapy based on the Traditional Chinese Medicine (TCM) theory of "treating both liver and heart." The trial compares the outcomes of patients receiving conventional therapy alone versus those receiving conventional therapy combined with GAI to determine improvements in auditory function, vestibular symptoms, and quality of life.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Meeting diagnostic criteria for SNHL with vertigo. * Disease course of 3 to 30 days. * Pure Tone Average (PTA) at 0.5, 1, 2, and 4 kHz between 30 and 90 dB HL. * Willingness to participate and sign informed consent. Exclusion Criteria: * Conductive or mixed hearing loss. * Hearing loss due to trauma, tumor, or infection. * Meniere's disease. * Severe systemic diseases (cardiovascular, cerebrovascular, renal, or hepatic). * Pregnancy or lactation. * Known allergy to any of the study medications.

What they're measuring

Change in Pure Tone Average (PTA)

Timeframe: Baseline and Week 4

Change in Dizziness Handicap Inventory (DHI) Score

Timeframe: Baseline and Week 4

Trial details

NCT IDNCT07283562

SponsorThe First Hospital of Hebei Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-31

View on ClinicalTrials.gov More Sensorineural Hearing Loss trials